NZ326031A - Use of olanzapine in the manufacture of a medicament for treating bipolar disorder - Google Patents

Use of olanzapine in the manufacture of a medicament for treating bipolar disorder

Info

Publication number: NZ326031A
Authority: NZ; New Zealand
Prior art keywords: olanzapine; bipolar disorder; medicament; patient; per day
Prior art date: 1996-03-11

Application number

NZ326031A

Other languages

English (en)

Inventor

Charles M Beasley

Gary D Tollefson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-11

Filing date

1996-12-04

Publication date

2001-05-25

1996-12-04 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2001-05-25 Publication of NZ326031A publication Critical patent/NZ326031A/en

Links

KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 56
229960005017 olanzapine Drugs 0.000 title claims abstract description 56
208000020925 Bipolar disease Diseases 0.000 title claims abstract description 43
239000003814 drug Substances 0.000 title claims abstract description 20
238000004519 manufacturing process Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 10
206010026749 Mania Diseases 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 7
208000024714 major depressive disease Diseases 0.000 claims description 7
238000002441 X-ray diffraction Methods 0.000 claims description 6
238000011282 treatment Methods 0.000 abstract description 17
239000000203 mixture Substances 0.000 description 15
238000000034 method Methods 0.000 description 9
235000011468 Albizia julibrissin Nutrition 0.000 description 8
241001070944 Mimosa Species 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000000843 powder Substances 0.000 description 5
208000028017 Psychotic disease Diseases 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000006735 deficit Effects 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
239000000463 material Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
238000000634 powder X-ray diffraction Methods 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000010949 copper Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
230000003001 depressive effect Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
239000007921 spray Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000002411 thermogravimetry Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000020186 Schizophreniform disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000009429 distress Effects 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000012066 reaction slurry Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
-1 sachet Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

NZ326031A 1996-03-11 1996-12-04 Use of olanzapine in the manufacture of a medicament for treating bipolar disorder NZ326031A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1315996P	1996-03-11	1996-03-11
PCT/US1996/019575 WO1997033577A1 (fr)	1996-03-11	1996-12-04	Methode de traitement des troubles bipolaires

Publications (1)

Publication Number	Publication Date
NZ326031A true NZ326031A (en)	2001-05-25

Family

ID=21758606

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ326031A NZ326031A (en)	1996-03-11	1996-12-04	Use of olanzapine in the manufacture of a medicament for treating bipolar disorder

Country Status (15)

Country	Link
EP (1)	EP0889725A4 (fr)
JP (1)	JP2000506859A (fr)
KR (1)	KR19990087713A (fr)
CN (1)	CN1213966A (fr)
AU (1)	AU734011B2 (fr)
BR (1)	BR9612548A (fr)
CZ (1)	CZ290298A3 (fr)
EA (1)	EA000758B1 (fr)
HU (1)	HUP9903679A3 (fr)
IL (1)	IL126162A0 (fr)
NO (1)	NO984189L (fr)
NZ (1)	NZ326031A (fr)
PL (1)	PL328925A1 (fr)
TR (1)	TR199801797T2 (fr)
WO (1)	WO1997033577A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6960577B2 (en)	1998-05-22	2005-11-01	Eli Lilly And Company	Combination therapy for treatment of refractory depression
WO1999061027A1 (fr) *	1998-05-22	1999-12-02	Eli Lilly And Company	Therapie combinee de traitement de la depression resistante
AU756468B2 (en) *	1998-05-29	2003-01-16	Eli Lilly And Company	Combination therapy for treatment of bipolar disorders
EP1133299A1 (fr)	1998-11-23	2001-09-19	Sepracor Inc.	Compositions a base de 2-hydroxymethylolanzapine et leurs utilisations
EP1135136B1 (fr) *	1998-11-23	2003-11-05	Sepracor Inc.	Compositions pharmaceutiques contenant de l'olanzapine-n-oxyde
WO2000030650A1 (fr) *	1998-11-23	2000-06-02	Sepracor Inc.	Compositions de desmethylolanzapine et methodes associees
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5457101A (en) *	1994-06-03	1995-10-10	Eli Lilly And Company	Thieno[1,5]benzoidiazepine use

1996
- 1996-12-04 CZ CZ982902A patent/CZ290298A3/cs unknown
- 1996-12-04 AU AU13307/97A patent/AU734011B2/en not_active Ceased
- 1996-12-04 KR KR1019980707180A patent/KR19990087713A/ko not_active Withdrawn
- 1996-12-04 CN CN96180183A patent/CN1213966A/zh active Pending
- 1996-12-04 EA EA199800819A patent/EA000758B1/ru not_active IP Right Cessation
- 1996-12-04 IL IL12616296A patent/IL126162A0/xx unknown
- 1996-12-04 TR TR1998/01797T patent/TR199801797T2/xx unknown
- 1996-12-04 PL PL96328925A patent/PL328925A1/xx unknown
- 1996-12-04 NZ NZ326031A patent/NZ326031A/en unknown
- 1996-12-04 WO PCT/US1996/019575 patent/WO1997033577A1/fr not_active Ceased
- 1996-12-04 HU HU9903679A patent/HUP9903679A3/hu unknown
- 1996-12-04 BR BR9612548A patent/BR9612548A/pt not_active Application Discontinuation
- 1996-12-04 JP JP9532570A patent/JP2000506859A/ja active Pending
- 1996-12-04 EP EP96944772A patent/EP0889725A4/fr not_active Withdrawn
1998
- 1998-09-11 NO NO984189A patent/NO984189L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU1330797A (en)	1997-10-01
NO984189D0 (no)	1998-09-11
KR19990087713A (ko)	1999-12-27
EP0889725A1 (fr)	1999-01-13
EA000758B1 (ru)	2000-04-24
WO1997033577A1 (fr)	1997-09-18
JP2000506859A (ja)	2000-06-06
TR199801797T2 (xx)	1998-12-21
AU734011B2 (en)	2001-05-31
HUP9903679A2 (hu)	2000-04-28
NO984189L (no)	1998-09-11
HUP9903679A3 (en)	2001-10-29
CZ290298A3 (cs)	1999-10-13
CN1213966A (zh)	1999-04-14
PL328925A1 (en)	1999-03-01
IL126162A0 (en)	1999-05-09
EP0889725A4 (fr)	2000-01-19
EA199800819A1 (ru)	1999-02-25
BR9612548A (pt)	1999-07-20

Publication	Publication Date	Title
AU734011B2 (en)	2001-05-31	Method for treating bipolar disorder
US6159963A (en)	2000-12-12	Method for treating substance abuse
AU709181B2 (en)	1999-08-26	Method for treating autism
US5744470A (en)	1998-04-28	Method for treating insomnia
EP1007050B1 (fr)	2005-05-18	L'olanzapine dans le traitement de la pharmacodependance
AU719517B2 (en)	2000-05-11	Method for treating excessive aggression
US6274636B1 (en)	2001-08-14	Method for treating a tic disorder
AU724245B2 (en)	2000-09-14	Method for treating insomnia
CA2248905A1 (fr)	1997-09-18	Methode de traitement des troubles bipolaires
GB2305859A (en)	1997-04-23	Treatment of obsessive-compulsive disorder
US6071902A (en)	2000-06-06	Method for treating excessive aggression
GB2305860A (en)	1997-04-23	Anti-emetic
AU725940C (en)	2001-05-17	Method for treating substance abuse
MXPA98007431A (en)	1999-04-06	Medications to treat the bipo disorder
MXPA98007438A (en)	1999-04-06	Medications to treat the insom

Legal Events

Date	Code	Title	Description
2001-09-28	PSEA	Patent sealed
2001-09-28	RENW	Renewal (renewal fees accepted)